Phosphatidylserine counteracts physiological and pharmacological suppression of humoral immune response

Vincenzo Guarcello, Giovanni Triolo, Matteo Cioni, Maria C. Morale, Zelinda Farinella, Umberto Scapagnini, Bianca Marchetti

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Phosphatidylserine (PS) is a necessary cofactor for protein kinase C (PKC) activation, and changes in the synthesis of PS have been shown to participate in the mechanism(s) involved in the transmembrane signaling of interleukin 1 (IL-1). In view of the age-associated defects in T-cell functions, in the present study we have addressed the question of whether an in vivo treatment with PS might interfere with such processes. Furthermore, the effect of an in vitro treatment with PS in human peripheral blood monocytes (PBMC) or splenocytes activated with a lectin mitogen, on the expression of IL-2 receptor, was assessed. While the process of ageing was accompanied by a marked decline of humoral response monitored by anti-BSA antibodies (of the IgG class) production, following immunization with BSA in complete Freund adjuvant, chronic treatment with PS (50 mg/kg, in drinking water), reversed this effect, raising specific antibody titers to levels practically indistinguishable from those measured in young animals. Pharmacological depression of humoral immune response induced by a treatment of adult animals with dexamethazone was similarly reversed by a chronic treatment with PS. While only a pharmacological concentration (10-5 M) of PS significantly increased IL-2 receptor expression in activated human PBMC, simultaneous treatment of PBMC with inactive doses of PS and the pharmacological activator of PKC (phorbol myristate acetate, PMA, 10-8 M) resulted in a synergistic stimulation of Tac+ cells. Furthermore, in cultures of rat splenocytes PS (10-6 M) significantly stimulated the expression of IL-2 receptor, and concomitant addition of PS (10-7 M) to Con A-stimulated splenocytes produced a significant potentiation of IL-2 receptor induction. The present results indicate that in vivo treatment of ageing animals with the specific phospholipid PS is able to reverse the physiological decline of the humoral immune response induced by the ageing process. Moreover, treatment of young rats with PS reversed the pharmacological associated depression of specific antibody production. The in vitro effects of the phospholipid on human PBMC and rat splenocytes might suggest that PS is implicated in T-cell activation through its action on IL-2 receptor.

Original languageEnglish
Pages (from-to)185-195
Number of pages11
JournalImmunopharmacology
Volume19
Issue number3
DOIs
Publication statusPublished - 1990

Fingerprint

Phosphatidylserines
Humoral Immunity
Pharmacology
Interleukin-2 Receptors
Monocytes
Therapeutics
Protein Kinase C
Phospholipids
T-Lymphocytes
Freund's Adjuvant
Immunoglobulin Isotypes
Tetradecanoylphorbol Acetate
Interleukin-1
Mitogens
Lectins
Drinking Water
Antibody Formation
Anti-Idiotypic Antibodies
Immunization
Immunoglobulin G

Keywords

  • Ageing
  • Antibody production
  • Immunosuppression
  • Interleukin 1
  • Interleukin 2 receptor
  • Lymphocyte
  • Phorbol myristate acetate
  • Phosphatidylserine
  • Phospholipid
  • Protein kinase C

ASJC Scopus subject areas

  • Pharmacology

Cite this

Phosphatidylserine counteracts physiological and pharmacological suppression of humoral immune response. / Guarcello, Vincenzo; Triolo, Giovanni; Cioni, Matteo; Morale, Maria C.; Farinella, Zelinda; Scapagnini, Umberto; Marchetti, Bianca.

In: Immunopharmacology, Vol. 19, No. 3, 1990, p. 185-195.

Research output: Contribution to journalArticle

Guarcello, Vincenzo ; Triolo, Giovanni ; Cioni, Matteo ; Morale, Maria C. ; Farinella, Zelinda ; Scapagnini, Umberto ; Marchetti, Bianca. / Phosphatidylserine counteracts physiological and pharmacological suppression of humoral immune response. In: Immunopharmacology. 1990 ; Vol. 19, No. 3. pp. 185-195.
@article{e06d988236fa4effa0e6613a2537e808,
title = "Phosphatidylserine counteracts physiological and pharmacological suppression of humoral immune response",
abstract = "Phosphatidylserine (PS) is a necessary cofactor for protein kinase C (PKC) activation, and changes in the synthesis of PS have been shown to participate in the mechanism(s) involved in the transmembrane signaling of interleukin 1 (IL-1). In view of the age-associated defects in T-cell functions, in the present study we have addressed the question of whether an in vivo treatment with PS might interfere with such processes. Furthermore, the effect of an in vitro treatment with PS in human peripheral blood monocytes (PBMC) or splenocytes activated with a lectin mitogen, on the expression of IL-2 receptor, was assessed. While the process of ageing was accompanied by a marked decline of humoral response monitored by anti-BSA antibodies (of the IgG class) production, following immunization with BSA in complete Freund adjuvant, chronic treatment with PS (50 mg/kg, in drinking water), reversed this effect, raising specific antibody titers to levels practically indistinguishable from those measured in young animals. Pharmacological depression of humoral immune response induced by a treatment of adult animals with dexamethazone was similarly reversed by a chronic treatment with PS. While only a pharmacological concentration (10-5 M) of PS significantly increased IL-2 receptor expression in activated human PBMC, simultaneous treatment of PBMC with inactive doses of PS and the pharmacological activator of PKC (phorbol myristate acetate, PMA, 10-8 M) resulted in a synergistic stimulation of Tac+ cells. Furthermore, in cultures of rat splenocytes PS (10-6 M) significantly stimulated the expression of IL-2 receptor, and concomitant addition of PS (10-7 M) to Con A-stimulated splenocytes produced a significant potentiation of IL-2 receptor induction. The present results indicate that in vivo treatment of ageing animals with the specific phospholipid PS is able to reverse the physiological decline of the humoral immune response induced by the ageing process. Moreover, treatment of young rats with PS reversed the pharmacological associated depression of specific antibody production. The in vitro effects of the phospholipid on human PBMC and rat splenocytes might suggest that PS is implicated in T-cell activation through its action on IL-2 receptor.",
keywords = "Ageing, Antibody production, Immunosuppression, Interleukin 1, Interleukin 2 receptor, Lymphocyte, Phorbol myristate acetate, Phosphatidylserine, Phospholipid, Protein kinase C",
author = "Vincenzo Guarcello and Giovanni Triolo and Matteo Cioni and Morale, {Maria C.} and Zelinda Farinella and Umberto Scapagnini and Bianca Marchetti",
year = "1990",
doi = "10.1016/0162-3109(90)90068-P",
language = "English",
volume = "19",
pages = "185--195",
journal = "Immunopharmacology",
issn = "0162-3109",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Phosphatidylserine counteracts physiological and pharmacological suppression of humoral immune response

AU - Guarcello, Vincenzo

AU - Triolo, Giovanni

AU - Cioni, Matteo

AU - Morale, Maria C.

AU - Farinella, Zelinda

AU - Scapagnini, Umberto

AU - Marchetti, Bianca

PY - 1990

Y1 - 1990

N2 - Phosphatidylserine (PS) is a necessary cofactor for protein kinase C (PKC) activation, and changes in the synthesis of PS have been shown to participate in the mechanism(s) involved in the transmembrane signaling of interleukin 1 (IL-1). In view of the age-associated defects in T-cell functions, in the present study we have addressed the question of whether an in vivo treatment with PS might interfere with such processes. Furthermore, the effect of an in vitro treatment with PS in human peripheral blood monocytes (PBMC) or splenocytes activated with a lectin mitogen, on the expression of IL-2 receptor, was assessed. While the process of ageing was accompanied by a marked decline of humoral response monitored by anti-BSA antibodies (of the IgG class) production, following immunization with BSA in complete Freund adjuvant, chronic treatment with PS (50 mg/kg, in drinking water), reversed this effect, raising specific antibody titers to levels practically indistinguishable from those measured in young animals. Pharmacological depression of humoral immune response induced by a treatment of adult animals with dexamethazone was similarly reversed by a chronic treatment with PS. While only a pharmacological concentration (10-5 M) of PS significantly increased IL-2 receptor expression in activated human PBMC, simultaneous treatment of PBMC with inactive doses of PS and the pharmacological activator of PKC (phorbol myristate acetate, PMA, 10-8 M) resulted in a synergistic stimulation of Tac+ cells. Furthermore, in cultures of rat splenocytes PS (10-6 M) significantly stimulated the expression of IL-2 receptor, and concomitant addition of PS (10-7 M) to Con A-stimulated splenocytes produced a significant potentiation of IL-2 receptor induction. The present results indicate that in vivo treatment of ageing animals with the specific phospholipid PS is able to reverse the physiological decline of the humoral immune response induced by the ageing process. Moreover, treatment of young rats with PS reversed the pharmacological associated depression of specific antibody production. The in vitro effects of the phospholipid on human PBMC and rat splenocytes might suggest that PS is implicated in T-cell activation through its action on IL-2 receptor.

AB - Phosphatidylserine (PS) is a necessary cofactor for protein kinase C (PKC) activation, and changes in the synthesis of PS have been shown to participate in the mechanism(s) involved in the transmembrane signaling of interleukin 1 (IL-1). In view of the age-associated defects in T-cell functions, in the present study we have addressed the question of whether an in vivo treatment with PS might interfere with such processes. Furthermore, the effect of an in vitro treatment with PS in human peripheral blood monocytes (PBMC) or splenocytes activated with a lectin mitogen, on the expression of IL-2 receptor, was assessed. While the process of ageing was accompanied by a marked decline of humoral response monitored by anti-BSA antibodies (of the IgG class) production, following immunization with BSA in complete Freund adjuvant, chronic treatment with PS (50 mg/kg, in drinking water), reversed this effect, raising specific antibody titers to levels practically indistinguishable from those measured in young animals. Pharmacological depression of humoral immune response induced by a treatment of adult animals with dexamethazone was similarly reversed by a chronic treatment with PS. While only a pharmacological concentration (10-5 M) of PS significantly increased IL-2 receptor expression in activated human PBMC, simultaneous treatment of PBMC with inactive doses of PS and the pharmacological activator of PKC (phorbol myristate acetate, PMA, 10-8 M) resulted in a synergistic stimulation of Tac+ cells. Furthermore, in cultures of rat splenocytes PS (10-6 M) significantly stimulated the expression of IL-2 receptor, and concomitant addition of PS (10-7 M) to Con A-stimulated splenocytes produced a significant potentiation of IL-2 receptor induction. The present results indicate that in vivo treatment of ageing animals with the specific phospholipid PS is able to reverse the physiological decline of the humoral immune response induced by the ageing process. Moreover, treatment of young rats with PS reversed the pharmacological associated depression of specific antibody production. The in vitro effects of the phospholipid on human PBMC and rat splenocytes might suggest that PS is implicated in T-cell activation through its action on IL-2 receptor.

KW - Ageing

KW - Antibody production

KW - Immunosuppression

KW - Interleukin 1

KW - Interleukin 2 receptor

KW - Lymphocyte

KW - Phorbol myristate acetate

KW - Phosphatidylserine

KW - Phospholipid

KW - Protein kinase C

UR - http://www.scopus.com/inward/record.url?scp=0025298769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025298769&partnerID=8YFLogxK

U2 - 10.1016/0162-3109(90)90068-P

DO - 10.1016/0162-3109(90)90068-P

M3 - Article

VL - 19

SP - 185

EP - 195

JO - Immunopharmacology

JF - Immunopharmacology

SN - 0162-3109

IS - 3

ER -